Somatostatin receptor 2

Lunit Presents Groundbreaking Study on Predicting Treatment Response by HER2 Analysis in Colorectal Cancer

Retrieved on:

Tuesday, August 1, 2023

SEOUL, South Korea, Aug. 1, 2023 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today announced the presentation of a groundbreaking study at the ASCO (American Society of Clinical Oncology) Breakthrough conference, to be held from August 3 to August 5 in Yokohama, Japan.

Key Points:

This study showcases the potential of Lunit SCOPE HER2, an AI-powered solution designed to detect HER2 expression profile in detail, to provide valuable insights that can predict treatment response, thereby advancing personalized medicine in mCRC patients.
The study employed a higher HER2 cutoff (HER2 3+ higher than 50%) than the standards used in breast and gastric cancers (HER2 3+ higher than 10%).
"This groundbreaking study marks a significant milestone for Lunit and reinforces our commitment to advancing personalized medicine in cancer treatment," said Brandon Suh, CEO of Lunit.
"The findings from this study demonstrate the potential of Lunit SCOPE HER2 to provide valuable insights in predicting treatment response for HER2-positive metastatic colorectal cancer patients.

Tarveda Therapeutics Presents Promising Phase 2 Data of PEN-221 in Gastrointestinal Mid-gut Neuroendocrine Tumors

Retrieved on:

Friday, June 4, 2021

Gastrointestinal neuroendocrine tumors are a disease with a significant unmet need.

Key Points:

Gastrointestinal neuroendocrine tumors are a disease with a significant unmet need.
This approach demonstrated encouraging efficacy results in the GI mid-gut NET cohort of the Phase 2 trial and was well tolerated by patients.
SSTR2 is overexpressed on the cell surface of a range of solid tumors including neuroendocrine tumors and small cell lung cancers.
PEN-221 is being evaluated in Phase 2a expansion cohorts enrolling patients with mid-gut neuroendocrine tumors, pancreatic neuroendocrine tumors, and small cell lung cancer (ClinicalTrials.gov Identifier: NCT02936323 ).

RadioMedix & Curium Announce Detectnetᵀᴹ (copper Cu 64 dotatate injection) Inclusion on NCCN Guidelines®

Retrieved on:

Wednesday, May 5, 2021

Branches of biology, Medical specialties, Organ systems, Radiopharmaceuticals, Orphan drugs, G protein-coupled receptors, Neuroendocrinology, Chelating agents, Somatostatin receptor 2, DOTA-TATE, Neuroendocrine tumor, Copper (64Cu) oxodotreotide

Louis, MO, May 05, 2021 (GLOBE NEWSWIRE) -- RadioMedix Inc. and its commercial partner Curium announced today that Detectnet is now included in the National Comprehensive Cancer Network\xc2\xae (NCCN) Clinical Practice Guidelines in Oncology \xe2\x80\x93 Neuroendocrine and Adrenal Tumors, version 1.2021 for the evaluation of neuroendocrine tumors (NETs).

Key Points:

Louis, MO, May 05, 2021 (GLOBE NEWSWIRE) -- RadioMedix Inc. and its commercial partner Curium announced today that Detectnet is now included in the National Comprehensive Cancer Network\xc2\xae (NCCN) Clinical Practice Guidelines in Oncology \xe2\x80\x93 Neuroendocrine and Adrenal Tumors, version 1.2021 for the evaluation of neuroendocrine tumors (NETs).
Effective April 1, 2021, all sites of care will use code A9592 to submit for reimbursement for all patients.
\xe2\x80\x9cThe Phase III results demonstrate the high sensitivity, specificity, and accuracy of Detectnet.
In published trials nausea immediately after injection was observed.\nNon-radioactive somatostatin analogs and copper Cu 64 dotatate competitively bind to somatostatin receptors (SSTR2).

RadioMedix & Curium Announce Detectnetᵀᴹ (copper Cu 64 dotatate injection) Inclusion on NCCN Guidelines®

Retrieved on:

Wednesday, May 5, 2021

Louis, MO, May 05, 2021 (GLOBE NEWSWIRE) -- RadioMedix Inc. and its commercial partner Curium announced today that Detectnet is now included in the National Comprehensive Cancer Network\xc2\xae (NCCN) Clinical Practice Guidelines in Oncology \xe2\x80\x93 Neuroendocrine and Adrenal Tumors, version 1.2021 for the evaluation of neuroendocrine tumors (NETs).

Key Points:

Louis, MO, May 05, 2021 (GLOBE NEWSWIRE) -- RadioMedix Inc. and its commercial partner Curium announced today that Detectnet is now included in the National Comprehensive Cancer Network\xc2\xae (NCCN) Clinical Practice Guidelines in Oncology \xe2\x80\x93 Neuroendocrine and Adrenal Tumors, version 1.2021 for the evaluation of neuroendocrine tumors (NETs).
Effective April 1, 2021, all sites of care will use code A9592 to submit for reimbursement for all patients.
\xe2\x80\x9cThe Phase III results demonstrate the high sensitivity, specificity, and accuracy of Detectnet.
In published trials nausea immediately after injection was observed.\nNon-radioactive somatostatin analogs and copper Cu 64 dotatate competitively bind to somatostatin receptors (SSTR2).

Kanazawa University research: Tracing tumors: targeting and imaging cancer cells

Retrieved on:

Tuesday, April 27, 2021

Carcinogenesis, Health, Immune system, Cancer cell, Cancer, Breast cancer, Clinical medicine, Medicine, Tumor, Oncology, Metastatic breast cancer, Somatostatin receptor 2

For example, platelet-derived growth factor receptor (PDGFR) which is often found on breast and colon cancer cells has been used to design probes that can attach to it and facilitate imaging of these cells.

Key Points:

For example, platelet-derived growth factor receptor (PDGFR) which is often found on breast and colon cancer cells has been used to design probes that can attach to it and facilitate imaging of these cells.
All such tracers designed to date have shown low accumulation within tumor tissues making it hard to visualize the cancer accurately.
Peptides are miniature proteins that quickly hustle into different organs in the body without attracting much attention from the immune system.
These two tracers also showed high uptake when incubated with cancer cells.

Kanazawa University research: Tracing tumors: targeting and imaging cancer cells

Retrieved on:

Tuesday, April 27, 2021

Carcinogenesis, Health, Immune system, Cancer cell, Cancer, Breast cancer, Clinical medicine, Medicine, Tumor, Oncology, Metastatic breast cancer, Somatostatin receptor 2

For example, platelet-derived growth factor receptor (PDGFR) which is often found on breast and colon cancer cells has been used to design probes that can attach to it and facilitate imaging of these cells.

Key Points:

For example, platelet-derived growth factor receptor (PDGFR) which is often found on breast and colon cancer cells has been used to design probes that can attach to it and facilitate imaging of these cells.
All such tracers designed to date have shown low accumulation within tumor tissues making it hard to visualize the cancer accurately.
Peptides are miniature proteins that quickly hustle into different organs in the body without attracting much attention from the immune system.
These two tracers also showed high uptake when incubated with cancer cells.

RadioMedix & Curium Announce Simplified Coding for DetectnetTM (copper Cu 64 dotatate injection)

Retrieved on:

Tuesday, March 23, 2021

Orphan drugs, Radiopharmaceuticals, Branches of biology, Drugs, Medicine, G protein-coupled receptors, Chelating agents, Macrocycles, DOTA-TATE, Somatostatin receptor 2, Copper (64Cu) oxodotreotide, Somatostatin

Ensure safe handling and preparation procedures to protect patients and health care workers from unintentional radiation exposure.

Key Points:

Ensure safe handling and preparation procedures to protect patients and health care workers from unintentional radiation exposure.
The uptake of copper Cu 64 dotatate reflects the level of somatostatin receptor density in NETs, however, uptake can also be seen in a variety of other tumors that also express somatostatin receptors.
A negative scan after the administration of Detectnet in patients who do not have a history of NET disease does not rule out disease.
Non-radioactive somatostatin analogs and copper Cu 64 dotatate competitively bind to somatostatin receptors (SSTR2).

RadioMedix & Curium Announce Permanent HCPCS Code for DetectnetTM (copper Cu 64 dotatate injection)

Retrieved on:

Tuesday, January 26, 2021

Ensure safe handling and preparation procedures to protect patients and health care workers from unintentional radiation exposure.

Key Points:

Ensure safe handling and preparation procedures to protect patients and health care workers from unintentional radiation exposure.
The uptake of copper Cu 64 dotatate reflects the level of somatostatin receptor density in NETs, however, uptake can also be seen in a variety of other tumors that also express somatostatin receptors.
A negative scan after the administration of Detectnet in patients who do not have a history of NET disease does not rule out disease.
Non-radioactive somatostatin analogs and copper Cu 64 dotatate competitively bind to somatostatin receptors (SSTR2).

RadioMedix & Curium Announce CMS Transitional Pass-Through Status for Detectnet™ (copper Cu 64 dotatate injection)

Retrieved on:

Wednesday, December 9, 2020

Branches of biology, Radiopharmaceuticals, Chemistry, Physical sciences, Chelating agents, Macrocycles, Neuroendocrinology, G protein-coupled receptors, DOTA-TATE, Copper (64Cu) oxodotreotide, Somatostatin receptor 2, Neuroendocrine tumor

The response to Detectnet in the neuroendocrine community has been tremendous, said Curium CEO, North America, Dan Brague.

Key Points:

The response to Detectnet in the neuroendocrine community has been tremendous, said Curium CEO, North America, Dan Brague.
The recent inclusion in a major Appropriate Use Criteria confirms the clinical utility of Detectnet in the neuroendocrine community, said Ebrahim Delpassand, MD, CEO of RadioMedix.
Detectnet is indicated for use with positron emission tomography (PET) for localization of somatostatin receptor positive neuroendocrine tumors (NETs) in adult patients.
Non-radioactive somatostatin analogs and copper Cu 64 dotatate competitively bind to somatostatin receptors (SSTR2).

RadioMedix and Curium Announce FDA Approval of Detectnet (copper Cu 64 dotatate injection) in the U.S.

Retrieved on:

Tuesday, September 8, 2020

Branches of biology, G protein-coupled receptors, Organ systems, Medicine, Neuroendocrinology, Somatostatin receptor 2, DOTA-TATE, Somatostatin, Peptide receptor radionuclide therapy, Advanced Accelerator Applications

Ensure safe handling and preparation procedures to protect patients and health care workers from unintentional radiation exposure.

Key Points:

Ensure safe handling and preparation procedures to protect patients and health care workers from unintentional radiation exposure.
The uptake of copper Cu 64 dotatate reflects the level of somatostatin receptor density in NETs, however, uptake can also be seen in a variety of other tumors that also express somatostatin receptors.
A negative scan after the administration of Detectnet in patients who do not have a history of NET disease does not rule out disease.
Non-radioactive somatostatin analogs and copper Cu 64 dotatate competitively bind to somatostatin receptors (SSTR2).